株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自閉症 : パイプライン分析

Autism - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232811
出版日 ページ情報 英文 134 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
自閉症 : パイプライン分析 Autism - Pipeline Review, H2 2016
出版日: 2016年07月27日 ページ情報: 英文 134 Pages
概要

自閉症とは、社会性の問題やコミュニケーション障害、行動の制限性、反復性、常同性などを特徴とする神経発達障害であり、性別、家族歴、脆弱X症候群、トゥレット症候群、癲癇などが素因となります。治療法には、SSRI(選択的セロトニン再取り込み阻害剤)、抗鬱剤、抗精神病薬、鎮静剤などの投与があります。

当レポートでは、世界における自閉症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

自閉症の概要

治療薬の開発

  • 自閉症向けパイプライン製品:概要
  • 自閉症向けパイプライン製品:比較分析

自閉症:開発中の治療薬:企業別

自閉症:開発中の治療薬:大学・研究機関別

自閉症:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

自閉症:開発中の製品:企業別

自閉症:開発中の製品:大学・研究機関別

自閉症:治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc.
  • AgeneBio Inc.
  • APeT Holding BV
  • Berg LLC
  • BioCrea GmbH
  • BrainStorm Cell Therapeutics Inc.
  • Cellceutix Corporation
  • Confluence Pharmaceuticals LLC
  • Curemark, LLC
  • Domain Therapeutics SA
  • F. Hoffmann-La Roche Ltd.
  • Heptares Therapeutics Limited
  • Intra-Cellular Therapies, Inc.
  • Luc Therapeutics, Inc.
  • MedDay
  • Omeros Corporation
  • 大塚ホールディングス
  • Retrophin Inc.
  • Sage Therapeutics, Inc.
  • Saniona AB
  • 大日本住友製薬

自閉症:治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (デキストロメトルファン + 硫酸キニジン)
  • ADX-71441
  • ADX-88178
  • アリピプラゾール
  • カルベトシン
  • CM-AT
  • 自閉症向け薬剤
  • ヒスタミン二塩酸塩
  • HTL-14242
  • ITI-007
  • KM-391
  • ルラシドン塩酸塩
  • MD-1103
  • niacinamide CR
  • oxytocin
  • RG-7314
  • SF-999
  • SGE-872
  • 中枢神経系障害治療用GABRA5 受容体作動薬
  • 自閉症治療用 GABAA 受容体サブユニット・アルファ5小分子作動薬
  • 自閉症治療用 GPR63標的薬
  • 自閉症・不安障害治療用オキシトシン標的薬
  • てんかん・自閉症治療用GABAA-Beta 2 受容体作動薬
  • 自閉症治療用代謝型グルタミン酸受容体4作動薬
  • 中枢神経系障害治療用 NMDA2A拮抗薬
  • 阻害剤 PI3K 自閉症・脆弱性X症候群治療用
  • 自閉症治療用/腫瘍学向け 翻訳開始因子-4E阻害剤
  • SNA-1
  • 多発性硬化症・関節リウマチ・骨関節炎・自閉症・気管支肺形成異常向け幹細胞療法
  • 神経変性疾患向け幹細胞療法
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8306IDB

Summary

Global Markets Direct's, 'Autism - Pipeline Review, H2 2016', provides an overview of the Autism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Autism
  • The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Autism therapeutics and enlists all their major and minor projects
  • The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Autism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Autism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Autism Overview
  • Therapeutics Development
    • Pipeline Products for Autism - Overview
    • Pipeline Products for Autism - Comparative Analysis
  • Autism - Therapeutics under Development by Companies
  • Autism - Therapeutics under Investigation by Universities/Institutes
  • Autism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Autism - Products under Development by Companies
  • Autism - Products under Investigation by Universities/Institutes
  • Autism - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aequus Pharmaceuticals Inc.
    • AgeneBio Inc.
    • APeT Holding BV
    • BioCrea GmbH
    • BrainStorm Cell Therapeutics Inc.
    • Cellceutix Corporation
    • Confluence Pharmaceuticals LLC
    • Coronis Partners Ltd.
    • Curemark, LLC
    • F. Hoffmann-La Roche Ltd.
    • GW Pharmaceuticals Plc
    • Heptares Therapeutics Limited
    • Intra-Cellular Therapies, Inc.
    • MedDay SA
    • Omeros Corporation
    • Otsuka Holdings Co., Ltd.
    • Retrophin Inc.
    • Saniona AB
    • Sumitomo Dainippon Pharma Co., Ltd.
  • Autism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dextromethorphan + quinidine sulfate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acamprosate calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carbetocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0306 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-AT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GWP-42006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • histamine dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-14242 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KM-391 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lurasidone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-1103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niacinamide CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NurOwn - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxytocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-999 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Chloride Channels for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR63 for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Autism and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Autism - Dormant Projects
  • Autism - Discontinued Products
  • Autism - Product Development Milestones
    • Featured News & Press Releases
      • Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
      • Dec 07, 2015: Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
      • Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
      • May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
      • Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment
      • Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
      • Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
      • Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
      • Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
      • Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
      • Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism
      • May 31, 2012: Study Reports New Treatment For Irritability In Autism
      • Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism
      • Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
      • Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Autism, H2 2016
  • Number of Products under Development for Autism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Autism - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Autism - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Autism - Pipeline by AgeneBio Inc., H2 2016
  • Autism - Pipeline by APeT Holding BV, H2 2016
  • Autism - Pipeline by BioCrea GmbH, H2 2016
  • Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2016
  • Autism - Pipeline by Cellceutix Corporation, H2 2016
  • Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
  • Autism - Pipeline by Coronis Partners Ltd., H2 2016
  • Autism - Pipeline by Curemark, LLC, H2 2016
  • Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Autism - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Autism - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Autism - Pipeline by MedDay SA, H2 2016
  • Autism - Pipeline by Omeros Corporation, H2 2016
  • Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Autism - Pipeline by Retrophin Inc., H2 2016
  • Autism - Pipeline by Saniona AB, H2 2016
  • Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Autism - Dormant Projects, H2 2016
  • Autism - Dormant Projects (Contd..1), H2 2016
  • Autism - Dormant Projects (Contd..2), H2 2016
  • Autism - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Autism, H2 2016
  • Number of Products under Development for Autism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top